Matthew J Glasgow1, Richard Edlin2, Jane E Harding3. 1. Liggins Institute, University of Auckland, Private Bag 92019, Grafton, Auckland, 1142, New Zealand. 2. School of Population Health, University of Auckland, Auckland, New Zealand. 3. Liggins Institute, University of Auckland, Private Bag 92019, Grafton, Auckland, 1142, New Zealand. j.harding@auckland.ac.nz.
Abstract
BACKGROUND: Neonatal hypoglycaemia is a common but treatable metabolic disorder that affects newborn infants and which, if not identified and treated adequately, may result in neurological sequelae that persist for the lifetime of the patient. The long-term financial and quality-of-life burden of neonatal hypoglycaemia has not been previously examined. METHODS: We assessed the postnatal hospital and long-term costs associated with neonatal hypoglycaemia over 80 year and 18 year time horizons, using a health-system perspective and assessing impact on quality of life using quality-adjusted life year (QALYs). A decision analytic model was used to represent key outcomes in the presence and absence of neonatal hypoglycaemia. RESULTS: The chance of developing one of the outcomes of neonatal hypoglycaemia in our model (cerebral palsy, learning disabilities, seizures, vision disorders) was 24.03% in subjects who experienced neonatal hypoglycaemia and 3.56% in those who do did not. Over an 80 year time horizon a subject who experienced neonatal hypoglycaemia had a combined hospital and post-discharge cost of NZ$72,000 due to the outcomes modelled, which is NZ$66,000 greater than a subject without neonatal hypoglycaemia. The net monetary benefit lost due to neonatal hypoglycaemia, using a value per QALY of NZ$43,000, is NZ$180,000 over an 80 year time horizon. CONCLUSIONS: Even under the most conservative of estimates, neonatal hypoglycaemia contributes a significant financial burden to the health system both during childhood and over a lifetime. The combination of direct costs and loss of quality of life due to neonatal hypoglycaemia means that this condition warrants further research to focus on prevention and effective treatment.
BACKGROUND:Neonatal hypoglycaemia is a common but treatable metabolic disorder that affects newborn infants and which, if not identified and treated adequately, may result in neurological sequelae that persist for the lifetime of the patient. The long-term financial and quality-of-life burden of neonatal hypoglycaemia has not been previously examined. METHODS: We assessed the postnatal hospital and long-term costs associated with neonatal hypoglycaemia over 80 year and 18 year time horizons, using a health-system perspective and assessing impact on quality of life using quality-adjusted life year (QALYs). A decision analytic model was used to represent key outcomes in the presence and absence of neonatal hypoglycaemia. RESULTS: The chance of developing one of the outcomes of neonatal hypoglycaemia in our model (cerebral palsy, learning disabilities, seizures, vision disorders) was 24.03% in subjects who experienced neonatal hypoglycaemia and 3.56% in those who do did not. Over an 80 year time horizon a subject who experienced neonatal hypoglycaemia had a combined hospital and post-discharge cost of NZ$72,000 due to the outcomes modelled, which is NZ$66,000 greater than a subject without neonatal hypoglycaemia. The net monetary benefit lost due to neonatal hypoglycaemia, using a value per QALY of NZ$43,000, is NZ$180,000 over an 80 year time horizon. CONCLUSIONS: Even under the most conservative of estimates, neonatal hypoglycaemia contributes a significant financial burden to the health system both during childhood and over a lifetime. The combination of direct costs and loss of quality of life due to neonatal hypoglycaemia means that this condition warrants further research to focus on prevention and effective treatment.
Authors: Jorien M Kerstjens; Inger F Bocca-Tjeertes; Andrea F de Winter; Sijmen A Reijneveld; Arend F Bos Journal: Pediatrics Date: 2012-07-09 Impact factor: 7.124
Authors: Jane E Harding; Deborah L Harris; Joanne E Hegarty; Jane M Alsweiler; Christopher Jd McKinlay Journal: Early Hum Dev Date: 2016-12-15 Impact factor: 2.079
Authors: Emily W Y Tam; Elysa Widjaja; Susan I Blaser; Daune L Macgregor; Prakash Satodia; Aideen M Moore Journal: Pediatrics Date: 2008-09 Impact factor: 7.124
Authors: Taygen Edwards; Gordon Liu; Malcolm Battin; Deborah L Harris; Joanne E Hegarty; Philip J Weston; Jane E Harding Journal: Cochrane Database Syst Rev Date: 2022-03-18